- Home
- CANF vs BBIO Comparison
CANF vs BBIO Comparison
Compare CANF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | BBIO |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 15.3B |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CANF | BBIO |
|---|---|---|
| Price | $3.13 | $68.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 25 |
| Target Price | ★ $9,750.00 | $83.96 |
| AVG Volume (30 Days) | 640.6K | ★ 2.2M |
| Earning Date | 03-27-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $461.72 | $88.16 |
| Revenue Next Year | $290,391.28 | $74.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $0.17 | $28.33 |
| 52 Week High | $10.40 | $84.94 |
Technical Indicators
Market Signals| Indicator | CANF | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 46.80 |
| Support Level | $0.47 | $61.95 |
| Resistance Level | $4.74 | $68.71 |
| Average True Range (ATR) | 0.29 | 2.75 |
| MACD | -0.15 | 0.27 |
| Stochastic Oscillator | 0.89 | 39.54 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.